- Approximately 600,000 people in the
United States live with tardive dyskinesia (TD), and about
65% have not yet been diagnosed1-3
- The diagnosis rate can be improved by increasing routine TD
screenings in people treated with antipsychotic
medication4
SAN
DIEGO, May 6, 2024 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) today renewed its commitment to
increasing awareness and advancing care for people living with TD
during Tardive Dyskinesia Awareness Week, May 5-11. TD is a persistent, involuntary
movement disorder associated with the use of antipsychotic
medication that may be necessary to treat individuals living with
mental illness, such as bipolar disorder, major depressive
disorder, schizophrenia and schizoaffective
disorder.1,5-7
For seven consecutive years, TD Awareness Week – which occurs
each year during Mental Health Awareness Month – has brought
together the mental health advocacy community and states across the
country to recognize the approximately 600,000 people in the U.S.
living with TD.1,2 This year, Neurocrine is joining
participants of TD Awareness Week to conduct initiatives nationwide
to decrease stigma, improve recognition and increase routine
screenings, diagnosis and awareness of appropriate treatment of
TD.
"TD Awareness Week increases dialogue around the physical,
social and emotional consequences the uncontrollable movements of
TD can have on individuals who are trying to manage their mental
health," said Josie Cooper,
Executive Director of the Movement Disorders Policy Coalition.
"It's important that we continue to work together to acknowledge
and increase support for people living with TD and to ensure they
receive the diagnosis and care they deserve."
TD is a chronic condition that is unlikely to improve without
treatment.1,4 The uncontrollable movements can affect
one's ability to work, drive, walk, button a shirt or eat and drink
and cause worry, frustration and
self-consciousness.2,8-10 It is critical that people
taking antipsychotic medication for mental illness be monitored by
a healthcare provider for drug-induced movement disorders, such as
TD.4,6 Routine screenings are essential for detection,
proper diagnosis and appropriate management to help improve
therapeutic outcomes.4
"The majority of people living with TD remain undiagnosed,
reinforcing the importance of proactive recognition and treatment
of the condition," said Eiry W. Roberts, M.D., Chief Medical
Officer, Neurocrine Biosciences. "We are committed to
partnering with all stakeholders during TD Awareness Week and
beyond to advocate for routine screenings for patients at risk for
TD."
The Meadows Mental Health Policy Institute, which provides
nonpartisan, data-driven and program guidance to improve mental
health services, released a recent report, in collaboration with
Neurocrine Biosciences, highlighting the importance of
measurement-based care (MBC) for people with a serious mental
illness who are treated with antipsychotics. MBC involves the
systematic use of validated rating scales to assess the
effectiveness of treatment and make adjustments as needed to
improve outcomes.11 For TD, MBC provides an effective
mechanism for earlier detection and the ability to develop and
routinely monitor an appropriate treatment plan for patients to
help improve outcomes.11 The full report can be accessed
at
https://mmhpi.org/project/increasing-measurement-based-assessment-and-care-for-people-with-serious-mental-illness/.
The 2020 American Psychiatric Association Practice Guideline for
the Treatment of Patients With Schizophrenia recommends screening
for TD at least every six months in high-risk patients and at least
every 12 months for others at risk of developing
TD.4
To learn more about TD, living with TD and how to treat TD,
visit TalkAboutTD.com.
About Tardive Dyskinesia Awareness Week
Since it began
in 2018, all 50 states, Washington, D.C., and various mental
health advocacy organizations have recognized the first full week
of May as Tardive Dyskinesia (TD) Awareness Week, which
acknowledges the approximately 600,000 Americans living with TD, an
involuntary movement disorder associated with taking antipsychotic
medication commonly prescribed to treat mental
illnesses. Participants in TD Awareness Week help to educate
people across the United States on
the potential physical, social and emotional consequences of TD and
the importance of speaking with a healthcare provider about the
occurrence and impact of the uncontrollable movements and available
treatment options.
As part of Neurocrine Biosciences' commitment to TD
education, more information is available
at Neurocrine.com/TD-Awareness, and resources are
available at TalkAboutTD.com. These resources can help
patients and care partners understand TD and recognize its
symptoms, request support and have a conversation with their
healthcare provider about ways to manage their TD, including
treatment options. Healthcare professionals can also
visit MIND-TD.com to learn about differential diagnosis
of TD and other movement disorders. For more information, follow
and join the conversation online by sharing #TDAwarenessWeek
#Screen4TD.
About Tardive Dyskinesia (TD)
Tardive dyskinesia (TD)
is a movement disorder that is characterized by uncontrollable,
abnormal and repetitive movements of the face, torso and/or other
body parts, which may be disruptive and negatively impact patients.
The condition is associated with taking certain kinds of mental
health medicines (antipsychotics) that help control dopamine
receptors in the brain. Taking antipsychotics commonly prescribed
to treat mental illnesses such as major depressive disorder,
bipolar disorder, schizophrenia and schizoaffective disorder, and
other prescription medicines (metoclopramide and prochlorperazine)
used to treat gastrointestinal disorders are associated with TD. In
patients with TD, these treatments are thought to result in
irregular dopamine signaling in a region of the brain that controls
movement. The symptoms of TD can be severe and are often persistent
and irreversible. TD is estimated to affect approximately 600,000
people in the United States.
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences is a leading neuroscience-focused,
biopharmaceutical company with a simple purpose: to relieve
suffering for people with great needs, but few options. We are
dedicated to discovering and developing life-changing treatments
for patients with under-addressed neurological,
neuroendocrine and neuropsychiatric disorders. The company's
diverse portfolio includes FDA-approved treatments for tardive
dyskinesia, chorea associated with Huntington's disease,
endometriosis* and uterine fibroids*, as well as a robust pipeline
including multiple compounds in mid- to late-phase clinical
development across our core therapeutic areas. For three decades,
we have applied our unique insight into neuroscience and the
interconnections between brain and body systems to treat complex
conditions. We relentlessly pursue medicines to ease the burden of
debilitating diseases and disorders, because you deserve brave
science. For more information, visit neurocrine.com, and follow the
company on LinkedIn, X (Formerly Twitter) and Facebook. (*in
collaboration with AbbVie)
NEUROCRINE BIOSCIENCES, NEUROCRINE and YOU DESERVE BRAVE
SCIENCE, are registered trademarks of Neurocrine Biosciences, Inc.
The Neurocrine logo is a trademark of Neurocrine Biosciences,
Inc.
References
- Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic
options for an increasingly common disorder.
Neurotherapeutics. 2014;11(1):166-176.
doi:10.1007/s13311-013-0222-5
- Data on file. Neurocrine Biosciences, Inc.
- Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia
prevalence in the period of second-generation antipsychotic use: a
meta-analysis. J Clin Psychiatry. 2017;78(3):e264–e278.
doi:10.4088/JCP.16r10832
- Keepers GA, Fochtmann LJ, Anzia JM, et al. The American
Psychiatric Association practice guideline for the treatment of
patients with schizophrenia. Am J Psychiatry.
2020;177(9):868-872. doi:10.1176/appi.ajp.2020.177901
- American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders. 5th ed. Text Revision. American
Psychiatric Association; 2023.
- Guy W. ECDEU Assessment Manual for Psychopharmacology.
National Institute of Mental Health; 1976.
- Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement
disorders induced by antipsychotic drugs: implications of the CATIE
schizophrenia trial. Neurol Clin. 2011;29(1):127-148.
doi:10.1016/j.ncl.2010.10.002
- Task Force on Tardive Dyskinesia. Tardive dyskinesia: a task
force report of the American Psychiatric Association; 1992.
- Boumans CE, de Mooij KJ, Koch PA, van 't Hof MA, Zitman FG. Is
the social acceptability of psychiatric patients decreased by
orofacial dyskinesia? Schizophr Bull. 1994;20(2):339-344.
doi:10.1093/schbul/20.2.339
- Yassa R. Functional impairment in tardive dyskinesia: medical
and psychosocial dimensions. Acta Psychiatr Scand.
1989;80(1):64-67. doi:10.1111/j.1600-0447.1989.tb01301
- Increasing measurement-based assessment and care for people
with serious mental illness. Meadows Mental Health Policy
Institute. Published January 2024.
Accessed March 1, 2024.
https://mmhpi.org/project/increasing-measurement-based-assessment-and-care-for-people-with-serious-mental-illness/
© 2024 Neurocrine Biosciences, Inc. All Rights Reserved.
CP-TD-US-1569 05/2024
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-supports-tardive-dyskinesia-awareness-week-by-advocating-for-routine-screening-and-monitoring-302135994.html
SOURCE Neurocrine Biosciences, Inc.